High cure rates for HCV genotype 6 in advanced liver fibrosis with 12 weeks sofosbuvir and daclatasvir: The Vietnam SEARCH Study

High cure rates for HCV genotype 6 in advanced liver fibrosis with 12 weeks sofosbuvir and daclatasvir: The Vietnam SEARCH Study

Background Genotype 6 is the most genetically diverse lineage of hepatitis C virus (HCV), and predominates in Vietnam. It can be treated with sofosbuvir with daclatasvir (SOF/DCV), the lowest costing treatment combination globally. In regional guidelines, longer treatment durations of SOF/DCV (24 we...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Flower, B, McCabe, L, Ngoc, CL, Hung, LM, Phuong, LT, Trong, TD, Thi, TV, Kim, HVT, Tat, TN, Hong, DPT, Chau, ANT, Thi, TD, Tuyet, NTT, Tarning, J, Kingsley, C, Kestelyn, E, Pett, SL, Thwaites, G, Chau, NVV, Smith, D, Barnes, E, Ansair, A, Turner, H, Rahman, M, Walker, AS, Day, J, Cooke, GS
Formáid:	Journal article
Teanga:	English
Foilsithe / Cruthaithe:	Oxford University Press 2021

Míreanna comhchosúla

Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study
de réir: Barnaby Flower, et al.
Foilsithe / Cruthaithe: (2023-01-01)

Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study
de réir: Flower, B, et al.
Foilsithe / Cruthaithe: (2023)

Combination of Sofosbuvir-Ledipasvir and Sofosbuvir- Daclatasvir for Treatment HCV Patients in Indonesia
de réir: Andri Sanityoso Sulaiman, et al.
Foilsithe / Cruthaithe: (2023-12-01)

TREATMENT OF HCV INFECTION BY A COMBINATION OF SOFOSBUVIR AND DACLATASVIR
de réir: Y. O. SHULPEKOVA, et al.
Foilsithe / Cruthaithe: (2017-05-01)

Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C
de réir: Andrew Hill, et al.
Foilsithe / Cruthaithe: (2016-01-01)

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
de réir: Phil McEwan, et al.
Foilsithe / Cruthaithe: (2017-07-01)

Decreased in Liver Fibrosis in Patients with HCV/HIV Coinfection After Treatment with Sofosbuvir/Daclatasvir
de réir: Andreas Jonathan, et al.
Foilsithe / Cruthaithe: (2020-07-01)

Treatment with Sofosbuvir and Daclatasvir (with or without Ribavirin) Improves Patient Reported Outcomes in Hepatitis C
de réir: Lucas Pereira Jorge de Medeiros, et al.
Foilsithe / Cruthaithe: (2018-04-01)

Safety and Efficacy of Sofosbuvir and Daclatasvir in The Treatment of Chronic HCV Infection in Elderly Egyptian Patients
de réir: Mohamed G. Mohamed, et al.
Foilsithe / Cruthaithe: (2021-01-01)

Efficacy of generic sofosbuvir with daclatasvir compared to sofosbuvir/ledipasvir in genotype 4 hepatitis C virus: A prospective comparison with historical control
de réir: Hala Joharji, et al.
Foilsithe / Cruthaithe: (2023-01-01)

RESULTS OF THE USE OF SOFOSBUVIR IN COMBINATION WITH LEDIPASVIR OR DACLATASVIR FOR CHRONIC HEPATITIS C TREATMENT IN THE REPUBLIC OF BELARUS
de réir: S. V. Zhavoronok, et al.
Foilsithe / Cruthaithe: (2018-10-01)

Generic sofosbuvir and daclatasvir for treatment of hepatitis C virus infection in patients with sickle cell disease
de réir: Ahmed Moustafa, et al.
Foilsithe / Cruthaithe: (2024-09-01)

Frequency of Sustained Virologic Response in Hepatitis C Positive, Treatment Naïve Patients on Sofosbuvir and Daclatasvir
de réir: Islam Shah, et al.
Foilsithe / Cruthaithe: (2023-07-01)

Direct-acting antivirals sofosbuvir and daclatasvir attenuate carbon tetrachloride-induced liver fibrosis in mice
de réir: Mayadah M. Abdelsalam, et al.
Foilsithe / Cruthaithe: (2023-03-01)

Impact of Sofosbuvir and Daclatasvir therapy on the expression levels of inflammasomes in chronic hepatitis C infected patients
de réir: aya fergany, et al.
Foilsithe / Cruthaithe: (2022-10-01)

Retrospective study of hepatitis c virus relapse after treatment with sofosbuvir and daclatasvir with or without ribavirin
de réir: Mohamed DA Abd Alla, et al.
Foilsithe / Cruthaithe: (2018-01-01)

Sofosbuvir and Daclatasvir in Mono- and HIV-coinfected Patients with Recurrent Hepatitis C After Liver Transplant
de réir: Lluís Castells, et al.
Foilsithe / Cruthaithe: (2017-01-01)

Prevalence of Hepatitis C Virus Infection and Efficacy of Sofosbuvir–Velpatasvir and Sofosbuvir–Daclatasvir Treatment Regimens in End-stage Renal Disease Patients on Maintenance Hemodialysis
de réir: Mohammad Ashraf Bhat, et al.
Foilsithe / Cruthaithe: (2023-05-01)

High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients
de réir: Adriano Pellicelli, et al.
Foilsithe / Cruthaithe: (2020-05-01)

Circulating microRNAs as predictors of response to sofosbuvir + daclatasvir + ribavirin in in HCV genotype-4 Egyptian patients
de réir: Noha Anwar Hassuna, et al.
Foilsithe / Cruthaithe: (2022-12-01)

Efficacy of 8-week daclatasvir-sofosbuvir regimen in chronic hepatitis C: a systematic review and meta-analysis
de réir: Ahmed N. Farrag, et al.
Foilsithe / Cruthaithe: (2024-11-01)

Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis
de réir: Sperl J, et al.
Foilsithe / Cruthaithe: (2017-06-01)

Resistance-Associated Substitutions (RAS) and Clinical Factors as Determinants of Sofosbuvir-Daclatasvir Treatment Outcomes in Chronic Hepatitis C Patients
de réir: Juferdy Kurniawan, et al.
Foilsithe / Cruthaithe: (2024-10-01)

Serum MicroRNA profiles in chronic hepatitis C Egyptian patients before and after combined sofosbuvir and daclatasvir treatment
de réir: Wafaa M. Ezzat, et al.
Foilsithe / Cruthaithe: (2024-01-01)

Effectiveness of Combination Therapy of Sofosbuvir and Daclatasvir in Hepatitis C Positive Hemodialysis Patients Presenting to a Tertiary Care Hospital
de réir: Qurat Ul Ain, et al.
Foilsithe / Cruthaithe: (2023-10-01)

Sofosbuvir, ribavirin and pegylated interferon for a daclatasvir-resistent genotype 3 hepatitis C virus: case report and review
de réir: Marcos Mucenic, et al.
Foilsithe / Cruthaithe: (2019-02-01)

The outcome of Daclatasvir and low dose Sofosbuvir therapy in end-stage renal disease patients with hepatitis C virus infection
de réir: M. Mostafi, et al.
Foilsithe / Cruthaithe: (2020-04-01)

The Efficacy of Generic Daclatasvir-Sofosbuvir as Pan-Genotypic Regiment for Hepatitis C Virus (HCV) Infected Patients in Bandung Indonesia
de réir: Muhammad Begawan Bestari, et al.
Foilsithe / Cruthaithe: (2020-07-01)

Efficacy and safety of sofosbuvir and daclatasvir in patients with chronic hepatitis C virus induced cirrhosis with Child-Pugh class B
de réir: Mayssa El Raziky, et al.
Foilsithe / Cruthaithe: (2022-01-01)

Daclatasvir, sofosbuvir with or without ribavirin for 24 weeks in hepatitis C genotype 3 cirrhosis: A real-life study
de réir: Raffaella Lionetti, et al.
Foilsithe / Cruthaithe: (2019-05-01)

Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan
de réir: Pin-Nan Cheng, et al.
Foilsithe / Cruthaithe: (2019-05-01)

Daclatasvir and Sofosbuvir Therapy Enhance Monocyte Phenotypic Changes in Naive Chronic Hepatitis C Patients: A Prospective Cohort Study
de réir: Hanan M. Fayed, et al.
Foilsithe / Cruthaithe: (2019-01-01)

Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study
de réir: Rodolfo Sacco, et al.
Foilsithe / Cruthaithe: (2020-12-01)

Daclatasvir-Sofosbuvir Combination Therapy with or without Ribavirin for Hepatitis-C Virus Infection: An Experience from a Tertiary Care Hospital, Pakistan
de réir: Abeera Ahmed, et al.
Foilsithe / Cruthaithe: (2023-10-01)

Sofosbuvir Plus Daclatasvir in Treatment of Chronic Hepatitis C Genotype 4 Infection in a Cohort of Egyptian Patients: An Experiment the Size of Egyptian Village
de réir: Ossama Ashraf Ahmed, et al.
Foilsithe / Cruthaithe: (2018-01-01)

Validated Reversed-Phase Liquid Chromatographic Method with Gradient Elution for Simultaneous Determination of the Antiviral Agents: Sofosbuvir, Ledipasvir, Daclatasvir, and Simeprevir in Their Dosage Forms
de réir: Essam Ezzeldin, et al.
Foilsithe / Cruthaithe: (2020-10-01)

Rapid Virological Response (RVR) of Daclatasvir and Sofosbuvir Plus Ribavirin in Non-Cirrhotic, Treatment-Naive Patients of Hepatitis C Virus Genotype 3
de réir: Muhammad Sarfraz, et al.
Foilsithe / Cruthaithe: (2018-12-01)

Development of a Robust UPLC Method for Simultaneous Determination of a Novel Combination of Sofosbuvir and Daclatasvir in Human Plasma: Clinical Application to Therapeutic Drug Monitoring
de réir: Naser F. Al-Tannak, et al.
Foilsithe / Cruthaithe: (2018-01-01)

Predictors of response to daclatasvir in addition to sofosbuvir in hepatitis C virus-infected patients with stage 4 and 5 chronic kidney disease and patients on maintenance hemodialysis
de réir: Rasha Gawish, et al.
Foilsithe / Cruthaithe: (2025-01-01)

Acompanhamento farmacoterapêutico no tratamento com Sofosbuvir e Daclatasvir em paciente com Hepatite C e Câncer Metastático: um relato de caso.
de réir: Amanda dos Santos Teles Cardoso, et al.
Foilsithe / Cruthaithe: (2023-02-01)